3D Medicine's First Independently Developed New Drug Approved For Clinical Use

On January 29, 2020, 3D Medicines announced that the clinical trial application of its self-developed category 1 innovative drug 3D011 has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, marking the approval of 3D Medicines Already have the original research ability to research and develop innovative drugs with global intellectual property rights, which has laid a solid foundation for achieving the company’s long-term sustainable development strategic goals.

3D011 Drug Clinical Trial Approval Notice (Picture source 3D Medicine)

3D011 is a class I innovative drug for the treatment of advanced solid tumors. The parent drug has a good inhibitory effect on related kinases. Clinical data has fully proved its good anti-tumor efficacy. The R&D team of 3D Medicine improved its pharmacokinetic properties through prodrug design, thereby reducing its systemic toxicity, and obtained the innovative drug 3D011.

❖ Medicilon’s Synthetic Chemistry Services

Medicilon can undertake the synthesis of special reagents, intermediates and molecular fragments, preparation of standard products, synthesis design and preparation of impurities or metabolites, synthesis of stable isotope internal standards and synthesis of tritiated compounds.

Aim at chemical synthesis through Ibuprofen

Medicilon FTE services & FFS services - flexible and efficient cooperation model

Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism

Medicilon was fortunate to cooperate with 3D Medicine in the 3D011 research and development project. Under the guidance of 3D Medicine’s R&D team, Medicilon’s pharmaceutical research team helped 3D Medicine overcome the difficulties in the process of drug synthesis and purification and helped it complete the development of APIs.
Medicilon congratulates the phased success of the 3D011 project, and looks forward to cooperating with 3D Medicine and many innovative drug companies in the future to create a thriving and flourishing innovative drugs, and to watch a new chapter in human health!

About 3D Medicine

3D Medicines Inc. is a biomedical company in the stage of advanced clinical development and early commercialization. Adhering to the concept of “helping cancer patients live longer and better”, it aims at the future trend of slowing cancer treatment , Focusing on developing a new generation of differentiated tumor immunotherapy drugs for cancer patients around the world, extending the survival time of cancer patients and improving the quality of life of patients. The company’s product line includes a new generation of biomacromolecule drugs and small molecule chemical drugs, and has a team with international new drug development, registration and commercial operation capabilities.

About Medicilon

Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai. It is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. Medicilon’s one-stop integrated service helps customers accelerate the development of new drugs with strong project management and more efficient and cost-effective R&D services. The services cover the entire process of preclinical new drug research in medicine, including drug discovery, pharmaceutical research and clinical trials, pre-research. Medicilon grows together with high-quality customers at home and abroad, and provides new drug research and development services to more than 700 customers around the world. Medicilon will continue to base itself on a global perspective, gather Chinese innovation, and contribute to human health!

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

What is Toxicokinetics?

Toxicokinetics is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms toxicokinetics , pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...

阅读全文

Shanghai Medicilon Inc.

搜索此博客